<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03359980</url>
  </required_header>
  <id_info>
    <org_study_id>MPOH03</org_study_id>
    <nct_id>NCT03359980</nct_id>
  </id_info>
  <brief_title>Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer</brief_title>
  <acronym>HERACLES</acronym>
  <official_title>Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaaT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaaT Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have a gastrointestinal acute Graft versus host disease (GVHD) received a
      first-line standard treatment of corticosteroids. For patients who do not respond or progress
      after an initial response have a high mortality. There is an interest in identifying
      effective second line therapy for these patients corticosteroid-resistant acute GVHD. Fecal
      microbiota transfer might be a beneficial treatment in this clinical situation with a poor
      prognosis and limited therapeutic options.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">January 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of FMT in the treatment of Steroid Refractory -Gastro-intestinal Acute GVHD (SR-GI-aGVHD) at D28 post inclusion</measure>
    <time_frame>up to 4 weeks post inclusion</time_frame>
    <description>Proportion of patients achieving GI and overall GVHD response by D28, defined as Complete response (CR) or Very Good Partial Response (VGPR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of FMT in patients with SR-GI-aGVHD</measure>
    <time_frame>through study completion, an average of six months</time_frame>
    <description>The overall safety of the study will be evaluated with the incidence of all Adverse Events (AEs) and Serious Adverse Events (SAEs) (frequency, grade, relationship) throughout the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with infectious disorders</measure>
    <time_frame>through study completion, an average of six months</time_frame>
    <description>Evaluation of FMT activity on infectious disorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of multidrug resistant bacteria in faeces</measure>
    <time_frame>through study completion, an average of six months</time_frame>
    <description>Evaluation of FMT activity on multidrug-resistant bacteria (MDRB) carriage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Chronic GVHD</measure>
    <time_frame>through study completion, an average of six months</time_frame>
    <description>Chronic GVHD expression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Fecal Microbiota Transplantation</condition>
  <arm_group>
    <arm_group_label>treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with Fecal Microbiota Transfer (FMT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fecal microbiota transfer</intervention_name>
    <description>transfer of fecal microbiota from healthy donors to the patients</description>
    <arm_group_label>treated patients</arm_group_label>
    <other_name>MaaT013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who develop a first episode of Stage 2 to 4 Gastro-intestinal Acute
             Graft-versus-Host (GI-aGVHD) with gut predominance (Przepiorka D, 1995), resistant to
             a first line therapy with steroids (lack of improvement after 5 days or progression
             after 3 days of treatment with corticosteroids at 2 mg/Kg methylprednisolone
             equivalent dose) (SR GI-aGVHD)

          -  Age ≥ 18 years old

          -  Allogeneic Hematopoietic stem cell transplantation (Allo-HSCT) with any type of donor,
             stem cell source, GVHD prophylaxis or conditioning regimen

          -  Patients able to have a minimum of 12 hours discontinuation of systemic antibiotics in
             order to perform the allogeneic FMT

          -  Signature of informed and written consent by the subject or by the subject's legally
             acceptable representative

        Exclusion Criteria:

          -  Grade IV hyper-acute GVHD

          -  Overlap chronic GVHD

          -  Acute GVHD after donor lymphocytes infusion

          -  Relapsed/persistent malignancy requiring rapid immune suppression withdrawal

          -  Active uncontrolled infection according to the attending physician

          -  Other systemic drugs than corticosteroids for GVHD treatment (including
             extra-corporeal photopheresis). Drugs already being used for GVHD prevention (eg.
             calcineurin inhibitors) are allowed.

          -  Absolute neutrophil count &lt; 0.5 x 10^9 /L

          -  Absolute platelet count &lt; 10 000

          -  Patient Epstein-Barr Virus (EBV) negative

          -  Evidence of toxic megacolon or gastrointestinal perforation on abdominal X-ray

          -  Known allergy or intolerance to trehalose or maltodextrin

          -  Pregnancy: positive urinary or blood test in female of childbearing potential;
             lactation; absence of effective contraceptive method for female of childbearing
             potential

          -  Other ongoing interventional protocol that might interfere with the current study
             primary endpoint.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent Malard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint Antoine - PARIS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemelli Hospital</name>
      <address>
        <city>Roma</city>
        <zip>168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Hematologii i Transplantologii</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Clinic Hospital</name>
      <address>
        <city>Katowice</city>
        <zip>40-032</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical hospital</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2017</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

